secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolus, Inc. (EOLS)
CIK:        0001570562
Form:       8-K
Filed at:   2026-08-05T20:17:15+00:00
Accession:  0001628280-26-053384
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolus Q2 revenue $84.1M (+21% YoY); raises FY2026 guidance; adds Profhilo U.S. rights
--------------------------------------------------------------------------------

- Q2 net revenue $84.1M (+21% YoY); GAAP operating loss $4.5M; adjusted EBITDA $4.7M (vs -$7.9M prior year).
- Raises FY2026 revenue guidance to $330-337M; raises adjusted gross margin to 67.0-67.5%; narrows non-GAAP opex to $212-216M.
- Exclusive U.S. partnership for Profhilo (IBSA); peak revenue >$100M; U.S. launch expected 2030.
- Expands Estyme HA gel franchise into Canada, Australia, New Zealand; commercialization expected 2028.
- Cash $45.2M; $120M non-dilutive capacity; reaffirms 2028 outlook ($450-500M revenue, 13-15% adj EBITDA margin).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1570562/000162828026053384/0001628280-26-053384-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1570562/000162828026053384/eols-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-053384

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer